OncoMatch/Clinical Trials/NCT05072600
Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer
Is NCT05072600 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Pembrolizumab for bladder cancer.
Treatment: Pembrolizumab — This is a Phase II, single-arm, study of pembrolizumab as maintenance therapy in muscle-invasive bladder cancer (MIBC) participants who have received maximum TURBT and tri-modality treatment (TMT) and achieved CR. All participants will receive pembrolizumab monotherapy per 21 days no longer than 17 cycles until disease progression or death.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Urothelial Carcinoma
Disease stage
Excluded: Stage PN+
stage cT2-4N0M0，Urothelial carcinoma >50%
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: tri-modality therapy — after maximum TURBT
Has received maximum TURBT followed by tri-modality therapy
Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137)
Cannot have received: systemic anti-cancer therapy
Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to allocation
Cannot have received: radiotherapy
Exception: 1-week washout permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease
Has received prior radiotherapy within 2 weeks of start of study intervention
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05072600 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy, systemic anti-cancer therapy, radiotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages